FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 329:1572-1574 November 18, 1993 Number 21 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Respiratory infections in infants and children, and their complications, are responsible for enormous morbidity throughout the world and, particularly in the developing world, for substantial mortality. Of the numerous known microbial causes, respiratory syncytial virus is by far the most important agent causing lower respiratory tract disease in children in the developed world. It is also highly contagious and is responsible for yearly epidemics in which approximately half of all children under 18 months of age are infected. In this country, approximately 1 to 3 percent of infected infants are hospitalized with pneumonia or bronchiolitis¹. And, like many other . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Ellenberg, S. S., Epstein, J. S., Fratantoni, J. C., Scott, D., Zoon, K. C., Groothuis, J. R., Hemming, V. G., Siber, G. R., Top, F. H. (1994). A Trial of RSV Immune Globulin in Infants and Young Children: The FDA's View. NEJM 331: 203-205 [Full Text]